Insulet Corporation (PODD) Earnings Call Transcripts

Insulet Corporation's Latest Earnings Call - September 9, 2026

In the Q2 2026 earnings call, Insulet Corporation (PODD:US) reported a revenue decline due to lower retention and utilization in the type 2 diabetes segment, leading management to lower guidance for the fiscal year. Revenue for the quarter was $300 million, down from $350 million year-over-year, and the company expects a challenging environment with no improvement in attrition rates factored into their guidance. Management emphasized their commitment to addressing execution challenges and maintaining a strong pipeline of innovation, which they believe will drive future growth.

Reported metrics

Guidance from management

Insulet maintained a prudent approach to guidance, assuming no improvement from current trends in attrition and utilization for 2026. They expect the impact of recent strategic measures to materialize more significantly in 2027.

What management said

Yes. We -- I would say it was -- it happened. We saw it trending ahead of our expectations at an elevated rate in quarter 2. And we've identified several root causes of why we saw some elevated attrition levels, and we're taking actions. Those 5 actions I spoke about on the quarter 2 call, I'm happy to elaborate more.

No, I think we said that it's more than double. It's trending more than double that. And we don't disclose what our retention rates are now. It's something that we're looking at maniacally, so I have confidence in that. We're going to talk more about how these programs are progressing on the quarter 3 call. But we -- importantly, we're looking, Larry, at what our active customer base. All of our data goes to the cl...

What analysts pressed on

Analysts expressed concerns over the elevated attrition rates in the type 2 segment, questioning whether Insulet's execution challenges could hinder long-term growth. There were also inquiries about potential impacts from increasing competition and the effectiveness of management's strategic initiatives.

Main topics on the call

• Guidance Reduction — Insulet reduced its 2026 guidance primarily due to 'lower retention and utilization in type 2' diabetes patients. Management stated that '2/3 of the change was due to the type 2 issue,' indicating significant challenges ...
• Type 2 Market Opportunity — Management highlighted the type 2 diabetes market as a 'tremendous growth opportunity' with a total addressable market (TAM) of approximately $28 billion. They noted that AID has only about a 5% penetration in the basal/...
• Attrition Rates — Management acknowledged elevated attrition rates in the type 2 segment, stating that it is 'more than double' the historical rate for type 1. They are implementing measures to improve retention, with a focus on the criti...
• Innovation Pipeline — Insulet's management emphasized their robust innovation pipeline, including upcoming algorithm improvements and the launch of Omnipod 6. They believe these advancements will enhance clinical outcomes and drive adoption i...

Read the full Insulet Corporation transcript (September 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 90 Insulet Corporation earnings call transcripts on record, spanning January 14, 2020 to September 9, 2026. Based on this history, Insulet Corporation reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PODD

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

90

First call

January 14, 2020

Most recent

September 9, 2026

Reporting cadence

quarterly